Wird geladen...
Objective cerebrospinal fluid response to intraventricular rituximab in indolent CNS lymphoma
Indolent CNS lymphomas (CNSLs) are rare and no guidelines exist for management. Recent literature highlights the potential for safe and tolerable intrathecal (IT) delivery of rituximab, a large anti-CD20 monoclonal antibody, for aggressive CNSL. We report a patient with relapsed indolent CNSL who fa...
Gespeichert in:
| Veröffentlicht in: | CNS Oncol |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Future Medicine Ltd
2015
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4778415/ https://ncbi.nlm.nih.gov/pubmed/25905905 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/cns.15.3 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|